Opus Genetics, Inc.
IRD Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$3.46
KIRA · Stoqly’s AI analyst, in plain words
- Opus Genetics, Inc. had $14.2M of revenue in fiscal 2025, up 29.1% on the year before.
- Its operating margin was −271.9%, up 292.8 pts: of every 100 in sales, about −272 is left after running the business.
- Opus Genetics, Inc. lost $49.6M in fiscal 2025.
- Opus Genetics, Inc. has $44.0M more cash than debt.
Market cap
$385M
P/E
—
Revenue
$14.2M
Net income
−$49.6M
Free cash flow
—
Operating margin
−271.9%
Opus Genetics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+29.1%
Yes. Sales grew 29.1% last year.
Does it make a profit?
−349.3%
No. It lost money last year.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Opus Genetics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Opus Genetics, Inc.
- CIK
- 0001228627
Opus Genetics, Inc. · IRD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.6M | $39.9M | $19.0M | $11.0M | $14.2M |
| Revenue growth | — | 6,665.7% | −52.2% | −42.3% | 29.1% |
| Operating margin | −3,854.8% | 45.7% | −55.5% | −564.7% | −271.9% |
| Net income | −$56.7M | $17.9M | −$10.0M | −$57.5M | −$49.6M |
| Net margin | −9,625.3% | 44.9% | −52.4% | −523.4% | −349.3% |
| Diluted EPS | −$3.82 | $0.87 | −$0.46 | −$2.15 | −$0.80 |
| Cash | |||||
| Cash from operations | −$19.4M | $14.3M | −$1.1M | −$25.6M | −$35.3M |
| Share count change | 218.7% | 38.7% | 4.8% | 23.7% | 132.9% |
| Debt and strength | |||||
| Cash and short-term investments | $24.8M | $42.7M | $50.5M | $30.3M | $45.1M |
| Debt incl. finance leases | $0.5M | $0.0M | — | $0.0M | $1.1M |
| Shareholders' equity | $22.2M | $46.2M | $49.9M | $6.7M | $15.3M |
| Net debt / EBITDA | — | −2.3x | — | — | — |
| Current ratio | 6.8x | 17.8x | 13.3x | 3.2x | 6.4x |
| Interest coverage | −11,352.5x | 2,025.1x | — | — | −299.2x |
| Returns and quality | |||||
| Return on capital | — | 503.7% | — | — | — |
| Return on equity | −1,295.1% | 52.3% | −20.8% | −203.2% | −449.4% |
| Return on tangible equity | −255.1% | 38.7% | −20.0% | −855.6% | −323.1% |
| Piotroski F-score | 3 | 6 | 1 | 1 | 3 |
| Altman Z'' | −5.4 | 21.6 | 12.8 | −18.5 | −11.4 |
Insiders bought, 12 months
$0.3M
1 insider
Insiders sold, 12 months
$19.3M
7 insiders
Of sales under plans
1%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Opus Genetics, Inc. · IRD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.46 a share, the company is worth $385M.
Source: SEC EDGAR XBRL filings (CIK 0001228627). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.